21921-33-5Relevant articles and documents
1-ACRYLOYLIMIDAZOLIDINE-2-ONE COMPOUND
-
Paragraph 0071-0073, (2021/03/03)
To provide a compound that is expected to be applied to cell culture materials, temperature-responsive polymer materials and the like.SOLUTION: The present invention relates to a 1-acryloylimidazolidine-2-one compound represented by formula (1) (where R1a is a hydrogen atom, a C1 to 4 alkyl group, a benzyl group or an oxyalkyl group represented by formula (2). R2a is a hydrogen atom or a C1 to 4 alkyl group. R3a is a hydrogen atom or a methyl group).SELECTED DRAWING: None
IMIDAZO [1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
-
Paragraph 00666, (2017/11/04)
The invention provides substituted imidazo[1,5-a]pyrimidinyl carboxamide and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted imidazo[1,5-a]pyrimidinyl carboxamide compounds described herein include substituted 2-heterocyclyl-4-alkyl-imidazo[1,5-a]pyrirnidine-8-carboxamide compounds and variants thereof.
CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS
-
Paragraph 0331, (2015/10/28)
The subject matter herein is directed to carbazole-containing amide, carbamate, and urea derivatives and pharmaceutically acceptable salts or hydrates thereof of structural formula I wherein the variable R1, R2, R3, R4, R5, R6, R7, A, D, E, G, J, L, M, Q, a, and b are accordingly described. Also provided are pharmaceutical compositions containing the compounds of formula I to treat a Cry-mediated disease or disorder, such as diabetes, complications associated with diabetes, Cushing's syndrome, NASH, NAFLD, asthma, and COPD.